# Nuclide record perspective-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/companies/perspective-therapeutics/>
  a schema:Organization ;
  nuclide:kind "company" ;
  schema:identifier "perspective-therapeutics" ;
  schema:name "Perspective Therapeutics"@en ;
  schema:description "Lead-212 alpha-therapy company whose SSTR2 agent [212Pb]VMT-α-NET reported a 43% response rate in neuroendocrine tumours and is heading for phase 3."@en ;
  schema:url <https://nuclide.cc/companies/perspective-therapeutics/>, <https://perspectivetherapeutics.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.globenewswire.com/news-release/2026/08/10/3342260/0/en/perspective-therapeutics-provides-recent-business-highlights-and-reports-2q-2026-results.html>, <https://www.perspectivetherapeutics.com/pr/perspective-therapeutics-announces-clinical-collaboration-and-supply-agreement-with-merck-to-evaluate-212pbpsv359-in-combination-with-keytruda-pembrolizumab-in-fap-a-positive-solid-tumors> ;
  schema:addressCountry "US" ;
  nuclide:related <https://nuclide.cc/indications/nsclc/>, <https://nuclide.cc/indications/lung-net/>, <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/pb-212/> ;
  nuclide:indications <https://nuclide.cc/indications/neuroendocrine/> ;
  nuclide:technologies <https://nuclide.cc/technologies/targeted-alpha-therapy/> ;
  nuclide:targets <https://nuclide.cc/targets/sstr2/>, <https://nuclide.cc/targets/psma/> ;
  nuclide:drugs <https://nuclide.cc/drugs/pb-212-vmt-alpha-net/>, <https://nuclide.cc/drugs/pb-212-psv359/> ;
  nuclide:terms <https://nuclide.cc/terms/alpha-vs-beta/> ;
  nuclide:trials <https://nuclide.cc/trials/nct05655312/>, <https://nuclide.cc/trials/nct05636618/>, <https://nuclide.cc/trials/nct06710756/> .